wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38838227-BFB61C44-3F91-40F2-AEC3-5EFFC7F953BB
Q38838227-BFB61C44-3F91-40F2-AEC3-5EFFC7F953BB
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38838227-BFB61C44-3F91-40F2-AEC3-5EFFC7F953BB
Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR.
P2860
Q38838227-BFB61C44-3F91-40F2-AEC3-5EFFC7F953BB
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38838227-BFB61C44-3F91-40F2-AEC3-5EFFC7F953BB
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
87da4d47c32f88ae7278daacebf63e859db500df
P2860
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.